Meeting - United Kingdom
Are improved tumour models the key for better clinical outcomes for cancer patients?
The answer is a resounding yes. Drug developers all agree on the importance of looking critically at the current spectrum of models in order to achieve more predictive results faster. Optimising your current tumour models and exploring practical alternatives can lead to models that are significantly more representative of clinical outcomes, saving you precious time and money in the process.
Designed alongside experts from AstraZeneca, Eisai, Roche, MedImmune,Genentech and others, Tumour Models will arm you with the practical knowledge needed to devise more effective tumour models, ultimately leading to better decision making moving into the clinic. The agenda has been created specifically to help the industry optimise current tumour models, seek alternative solutions to common challenges and use tumour models to better predict drug efficacy. With presentations from Bayer, Sanofi, Roche and Actelion, this is too big an opportunity to miss.
Who should attend?
Drug developers who are looking to optimise current tumour models and explore practical alternatives to ensure the effective translation of preclinical data into a clinical setting
Academics and researchers looking to learn more about the most up to date tumour models, together with novel imaging techniques and alternate animal systems. It's also a great opportunity to look for collaborations and funding
Biotechs looking to showcase their optimised and alternative tumour model platforms
CRO's specialising in preclinical drug development and oncology
(Courtesy of NSC migration to experimental brain tumour in mouse model, via neurowiki2012.wikispaces.com)
Tue, Jan 29, 2013 - Thu, Jan 31, 2013
Strand Palace Hotel, 327 Strand, WC2R 0JJ, London, United Kingdom
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
